Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACD 856

Next Previous
Drug Profile

ACD 856

Alternative Names: ACD-856

Latest Information Update: 27 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AlzeCure
  • Class Antidementias; Antidepressants; Antiparkinsonians; Neuroprotectants; Nootropics; Sleep disorder therapies; Small molecules; Triazines
  • Mechanism of Action TrkA receptor agonists; TrkB receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cognition disorders

Highest Development Phases

  • Phase I Alzheimer's disease; Cognition disorders; Depressive disorders; Parkinson's disease; Sleep disorders; Traumatic brain injuries

Most Recent Events

  • 09 Apr 2026 AlzeCure completes a phase-Ib clinical trials in Cognition disorders, Depressive disorders, Alzheimer's disease) (In volunteers) in Sweden (unspecified route) (CTIS2025-522287-32-00)
  • 13 Oct 2025 Phase-I clinical trials in Depressive disorders (In volunteers) in Sweden (unspecified route) (AlzeCure Pharma pipeline, October 2025)
  • 13 Oct 2025 Phase-I clinical trials in Parkinson's disease (In volunteers) in Sweden (PO) (AlzeCure Pharma pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top